Injective (INJ) is currently priced at $3.29, reflecting a slight 24-hour change of 0.71%. The asset has experienced a daily range of $0.14, with a high of $3.31 and a low of $3.17, indicating moderate volatility within this period.

Volume stands at approximately 51.83 million, resulting in a volume-to-market cap ratio of 15.76%, suggesting healthy trading activity relative to its market capitalization. The hourly moving averages indicate bullish momentum, with the 8, 13, 21, and 55 SMAs all showing positive changes, reinforcing upward price action in the short term.

The 1-hour Relative Strength Index (RSI) is currently at 69, nearing overbought territory, while the 7-day RSI at 55 suggests neutral momentum. This divergence indicates that while the short-term outlook is positive, the medium-term momentum remains stable, without clear signs of exhaustion.

Over the last week, INJ has shown a price increase of approximately 11.65%, with a 14-day change of 11.64% and a 30-day change of 6.52%. These figures underscore a consistent upward trend in the asset’s performance, indicating strong buying interest over multiple time frames.

Despite the current price being significantly lower than its all-time high of $52.62 reached on March 14, 2024, the current trends suggest room for growth. The recent price actions combined with solid volume and positive moving averages support a bullish outlook for the asset.

Given the current technical indicators and recent performance metrics, a Buy rating is warranted for Injective (INJ). The positive price movements, coupled with healthy trading volume and supportive technical indicators, suggest potential for further gains in the near term.